Jaka jest cena za DelMar Pharmaceuticals, Inc. (DMPWW)

Cena za DelMar Pharmaceuticals, Inc. (DMPWW) wynosi $0.005

Jaka jest kapitalizacja rynkowa dla DelMar Pharmaceuticals, Inc. (DMPWW)

Kapitalizacja rynkowa dla DelMar Pharmaceuticals, Inc. (DMPWW) wynosi $1.74K

DelMar Pharmaceuticals, Inc. (DMPWW) EPS

Kintara Therapeutics, Inc., previously known as DelMar Pharmaceuticals, Inc. until its rebranding in August 2020, operates as a clinical-stage pharmaceutical firm. Headquartered in San Diego, California, and established in 2009, the company is committed to advancing and bringing to market anti-cancer treatments for patients. Its development pipeline includes two advanced therapeutic candidates. One is VAL-083, a DNA-targeting agent poised for Phase III trials, designed to combat various drug-resistant solid tumors such as glioblastoma multiforme, ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The other is REM-001, a late-stage photodynamic therapy intended for conditions like cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and addressing access graft failure in hemodialysis patients. Kintara Therapeutics also maintains a strategic alliance with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. for the manufacturing and commercialization of VAL-083 within the Chinese market.

Rok	EPS	Zmień
Za mało danych dla podanych dat.

Rok

EPS

Zmień

Za mało danych dla podanych dat.

Firma	EPS	Różnica w EPS	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	$13.70	-	BE
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR

Firma

EPS

Różnica w EPS

Kraj